Patrick - The complete set of word from them link you provided.
Licensing and availability
Fampridine was granted a conditional marketing authorisation by the European Medicines Agency (EMA) in July 2011. A conditional marketing authorisation is granted when a medicinal product is considered to fulfil an unmet medical need and should be made available despite the fact that further data are still required. The licence required the manufacturer, Biogen Idec, to carry out further research into the benefits and long-term safety of fampridine. This research was completed in 2016 and in May 2017 a standard marketing authorization (a full licence) was granted.
In 2014, the NICE MS Clinical Guideline 186 concluded that fampridine was not a cost effective treatment for lack of mobility in MS. Consequently, it is not recommended for use on the NHS in England and Wales.
In Scotland, fampridine is not recommended for use within the NHS as the Scottish Medicines Consortium (SMC) has not received a submission from the manufacturers of fampridine.
Some people with MS opt to pay privately for fampridine. The cost is around £4,700 per year (at October 2014).
So yes I agree totally that it was granted a CMA in July 2011, but as of 2014, guideline 186 concluded that it is not cost effective and therefor it is not available on the NHS… Please do not post items that are only half the story.